Robert Berkley, MD
Cardiovascular Disease · Las Vegas, NVNPI 1710092523
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Biotronik Inc. at 55.4% of the total. Reporting peaked in 2021 at $6,396 and has fallen 87.2% since, to $821 in 2025.
Across 253 payments — averaging $57.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$8K
- Medtronic$1K
- Boehringer Ingelheim$778
- Novartis$606
- Kestra Medical Technology Services, Inc.$497
- Impulse Dynamics (USA) Inc.$422
- plus $3K from 24 others
What the payments were for
- Consulting fees$7,20049%
- Travel & lodging$9777%
- Food & beverage$6,28943%
- Education$1131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 18 | $8,076 |
| Medtronic | 11 | $1,158 |
| Boehringer Ingelheim | 32 | $778 |
| Novartis | 33 | $606 |
| Kestra Medical Technology Services, Inc. | 10 | $497 |
| Impulse Dynamics (USA) Inc. | 6 | $422 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $415 |
| E.r. Squibb & Sons, L.L.C. | 15 | $362 |
| Johnson & Johnson | 18 | $290 |
| Merck | 10 | $267 |
| Pfizer | 21 | $235 |
| Amgen | 8 | $227 |
| Sanofi-aventis U.S. LLC | 8 | $149 |
| Abiomed | 1 | $138 |
| Novo Nordisk | 6 | $115 |
| AstraZeneca | 2 | $113 |
| Boston Scientific | 4 | $110 |
| Abbott | 5 | $96 |
| Amarin Pharma, Inc. | 5 | $71 |
| Cvrx, Inc. | 3 | $64 |
| Elutia, Inc. | 1 | $62 |
| Edwards Lifesciences | 2 | $51 |
| Kowa Pharmaceuticals America, Inc. | 3 | $50 |
| Esperion Therapeutics, Inc. | 2 | $46 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Bridgebio Pharma, Inc. | 1 | $31 |
| Philips North America LLC | 1 | $29 |
| Bayer | 1 | $22 |
| Acutus Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edora$5,131
- Rivacor$3,931
- Acticor$3,531
- Plexa$3,200
- Sentus$3,200
- Rivacor 7 DR-T$2,000
- Acticor 7 VR-T DX$1,331
- SelectSecure$734
- BioMonitor$445
- Solia$331
- Arctic Front$243
- OPTIMIZER$235
- Impella$138
- Repatha$125
- ELIQUIS$118
- Assure WCD$113
- JARDIANCE$106
How this compares
$14,578 in reported general payments places this provider in the 80th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 256 | $321,057 |
| XareltoRivaroxaban | 171 | $212,643 |
| EntrestoSacubitril/Valsartan | 137 | $178,663 |
| JardianceEmpagliflozin | 52 | $77,812 |
| BrilintaTicagrelor | 68 | $67,089 |
| FarxigaDapagliflozin Propanediol | 34 | $41,736 |
| VerquvoVericiguat | 20 | $39,215 |
| MultaqDronedarone Hcl | 18 | $38,859 |
| VascepaIcosapent Ethyl | 30 | $24,068 |
| Repatha SureclickEvolocumab | 17 | $15,868 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $7,011 |
| Midodrine Hcl | 17 | $3,374 |
| Metoprolol Succinate | 235 | $2,820 |
| Flecainide Acetate | 83 | $2,661 |
| Atorvastatin Calcium | 271 | $2,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $235 | $321,057256 claims |
| Johnson & JohnsonXarelto | $290 | $212,643171 claims |
| NovartisEntresto | $606 | $178,663137 claims |
| AstraZenecaBrilinta, Farxiga | $113 | $108,825102 claims |
| Boehringer IngelheimJardiance | $778 | $77,81252 claims |
| MerckVerquvo | $267 | $39,21520 claims |
| Sanofi-aventis U.S. LLCMultaq | $149 | $38,85918 claims |
| Esperion Therapeutics, Inc.Nexlizet | $46 | $7,01114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.